Sign in
CompletedNo phase

Multicenter Clinical Trial of a Phakic Implantable Collamer® Lens (ICL)

Key facts

Who runs it
Staar Surgical Company
Where
Bowie, Brecksville, Dallas, Draper, Honolulu, Indianapolis, King of Prussia, Omaha, Overland Park, Phoenix, Salt Lake City, San Antonio, Sioux Falls, and St Louis, United StatesSee the 14 sites
Trial code
Status
Completed
People taking part
327 people enrolled
Started
30 Jan 2020
Ended
15 Dec 2023
Type of study
Interventional, 2 groups
Treatments tested
  • EVO/EVO+ Visian ICL
Record updated
16 March 2026

Who can take part

Age
21 years to 45 years
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (11)Hide the full registry criteria

Who can take part

  • Moderate to high myopia or myopic astigmatism correctable with available EVO/EVO+ ICL powers
  • Stable refractive history within 0.50 D each cylinder and spherical equivalent (SE) for 1 year prior to implantation
  • Able and willing to return for scheduled follow-up examinations after surgery
  • Able to read, understand and provide written informed consent on the Institutional Review Board (IRB)-approved informed consent form (ICF) and provide authorization as appropriate for local privacy regulations
  • Other protocol-specified inclusion criteria may apply

Who cannot take part

  • History of previous ocular surgery
  • Insulin-dependent diabetes or diabetic retinopathy
  • Cataract of any grade
  • Monocular
  • Pregnant or nursing women, or those who plan to become pregnant over the course of this clinical study
  • Other protocol-specified exclusion criteria may apply

Where in United States

  • Solomon Eye Physicians and Surgeons/Bowie Vision InstituteBowie, United States
  • Cleveland Eye ClinicBrecksville, United States
  • Key-Whitman Eye CenterDallas, United States
  • Hoopes Vision/Hoopes, Durrie, Rivera ResearchDraper, United States
  • Aloha Laser Vision, LLCHonolulu, United States
  • Price Vision GroupIndianapolis, United States
  • Kremer Eye CenterKing of Prussia, United States
  • Kugler Vision, PCOmaha, United States
  • Durrie VisionOverland Park, United States
  • Barnett Dulaney PerkinsPhoenix, United States
  • The Eye Institute of UtahSalt Lake City, United States
  • Parkhurst NuVisionSan Antonio, United States
  • Vance Thompson VisionSioux Falls, United States
  • Brinton VisionSt Louis, United States

About the trial

What the trial wants to find out

This objective of this study is to evaluate the safety, and to collect supportive data on effectiveness of the EVO/EVO+ Visian® Implantable Collamer® Lens (ICL) in study participants who have a diagnosis of myopia or myopia with astigmatism. Primary study analysis will be evaluated when 300 primary eyes complete 6 months of follow-up. Final study analysis will be assessed when all treated eyes complete 36 months of follow-up.

The 2 groups in the trial

  • Primary EyesTreatment being tested

    First implanted eyes of enrolled participants

    Treatment: EVO/EVO+ Visian ICL

  • Fellow EyesTreatment being tested

    Second implanted eyes of enrolled participants

    Treatment: EVO/EVO+ Visian ICL

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Multicenter Clinical Evaluation of the EVO/EVO+ Visian® Implantable Collamer® Lens
Record updated
16 March 2026